The Global Emerging Interventional Cardiac Devices Market Increasing Adoption of New Technologies in Emerging Markets

Provides Impetus to Growth

ND01-54

February 2014

9 ND01-54

Executive Summary

10 ND01-54

Key Findings

• The total revenue generated by sales of emerging interventional cardiac devices globally

in 2013 was estimated to represent a 26.4% increase over the 2012 revenue.

• Revenue in the US market is projected to grow at a compound annual growth rate

(CAGR) of 33.6%, whereas revenue is projected to grow in the European market at

14.4% and in Rest of World (ROW) at 43.1%, indicating the highest growth.

• The emerging interventional cardiac devices market is currently in its growth phase; this

is attributed to increased levels of awareness of various technologies including renal

denervation (RDN), fractional flow reserve (FFR), and left atrial appendage (LAA) and

the availability of various products in the market.

• With the availability of innovative technologies and strong clinical data evidence, the

interventional cardiac devices market is expected to gain momentum in the marketplace.

• The US and European markets are the highest-growing regions in the interventional

cardiology space; however, the growth in these regions is likely to be offset by low

procedural volumes and declining average selling prices (ASPs).

Source: Frost & Sullivan

11 ND01-54

Key Findings (continued)

• With the increase in life expectancy and an aging baby-boomer population as well as the

surge in cardiac morbidities, the need for the emerging interventional cardiology market

is bound to increase dramatically by 2020.

• Of Brazil, Russia, India, China (BRIC), South Africa, and South Korea, India and China

contribute the highest growth in terms of CAGR and are a step ahead of regions such as

South Korea and Russia.

• Nonetheless, the BRIC interventional cardiology device market will increase robustly

over the forecast period. Outside of the BRIC nations, other highly targeted countries

include Australia, Turkey, Indonesia, Malaysia, and Mexico.

Source: Frost & Sullivan

12 ND01-54

Scope and Segmentation

Scope

Geographic Coverage Global: United States, Europe, and ROW

Study Period 2010–2020

Base Year 2013

Forecast Period 2014–2020

Monetary Unit US dollars

Source: Frost & Sullivan

13 ND01-54

Scope and Segmentation (continued)

• This research service analyses key data and information and provides an in-depth analysis of the global

emerging interventional cardiac devices market.

• The study period covered by this service for the emerging interventional cardiac devices market is from

2010 to 2020, with a CAGR period from 2013 to 2020; the base year is 2013, and the forecast period is

from 2014 to 2020.

• The key geographic areas covered in this study include the United States, Europe, and ROW.

• The 5 key segments covered in this study include transcatheter aortic valve replacement (TAVR), renal

denervation (RDN), bronchial thermoplasty (BT), bioresorbable stents, and FFR. This study does not

include other emerging interventional device market segments.

• This study looks at a series of emerging early-stage interventional technologies; as such, it is approved as

is, and there does not need to be an aggregate total market forecast.

• Revenue for emerging interventional cardiac devices manufacturing companies was obtained from

companies’ annual reports and financial statements.

Source: Frost & Sullivan

14 ND01-54

Key Questions This Study Will Answer

Is the interventional cardiac devices market growing, how long will it continue to grow, and at what rate?

What are the key drivers and trends that lead to growth opportunities?

Which are the most promising segments for manufacturing companies to venture into? Who are the key market participants in each segment?

What market predictions for the forecast period will likely affect manufacturers in the interventional cardiac devices market?

Are the products and services offered today meeting customer needs, or is additional development needed?

What are the trends in use and technology, and is there a shift towards any particular product segment?

Source: Frost & Sullivan

15 ND01-54

Compound

Annual Growth

Rate (CAGR)

24.5%

(CAGR, 2013–2020)

Executive Summary—Market Engineering Measurements

Market Stage

Growth

Market Revenue

$1.49 B

(2013)

Market Size for

Last Year of

Study Period

$6.93 B

(2020)

Base Year

Market Growth

Rate

25.2%

Customer Price

Sensitivity

7

(scale:1 [Low] to 10 [High])

Degree of

Technical

Change

7

(scale:1 [Low] to 10 [High])

Total Emerging Interventional Cardiac Devices Market: Global, 2013

For a tabular version click here. Stable Increasing Decreasing

Note: All figures are rounded. The base year is 2013. Source: Frost & Sullivan

Number of

Competitors

More than 15

(active market competitors in base year)

n

Competitor Overview

Market Overview

16 ND01-54

CEO’s Perspective

2 Significant growth of RDN is expected from various other regions, including Canada, Australia, and Latin America.

3 Favourable demographics will continue to drive the adoption of interventional cardiac devices in growing economies.

4 Technology advances will be witnessed especially in areas of bioresorbable stents and LAA.

5

A significant rise in revenue of coronary stents will be witnessed due to the growing adoption of premium-priced drug-eluting stents.

1 Drug-eluting stents may present regulatory and reimbursement challenges across

different regions.

Source: Frost & Sullivan

17 ND01-54

Executive Summary—3 Big Predictions

2 The price of the devices is increasingly becoming a major factor in competitiveness.

3 An increase in minimally invasive procedures is expected to drive the growth of the market in the next few years.

1 With the increasing use of interventional cardiac procedures, the APAC region is under tremendous pressure to increase the number of trained and skilled medical personnel.

Source: Frost & Sullivan